Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Depreciation & Amortization (CF) (2016 - 2025)

Historic Depreciation & Amortization (CF) for Ptc Therapeutics (PTCT) over the last 14 years, with Q3 2025 value amounting to $11.1 million.

  • Ptc Therapeutics' Depreciation & Amortization (CF) rose 7127.66% to $11.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $32.7 million, marking a year-over-year decrease of 7815.77%. This contributed to the annual value of $75.7 million for FY2024, which is 6801.94% down from last year.
  • Per Ptc Therapeutics' latest filing, its Depreciation & Amortization (CF) stood at $11.1 million for Q3 2025, which was up 7127.66% from $7.6 million recorded in Q2 2025.
  • In the past 5 years, Ptc Therapeutics' Depreciation & Amortization (CF) ranged from a high of $80.7 million in Q4 2023 and a low of $6.5 million during Q3 2024
  • Its 5-year average for Depreciation & Amortization (CF) is $28.0 million, with a median of $18.8 million in 2021.
  • In the last 5 years, Ptc Therapeutics' Depreciation & Amortization (CF) surged by 10765.47% in 2023 and then tumbled by 9161.89% in 2024.
  • Ptc Therapeutics' Depreciation & Amortization (CF) (Quarter) stood at $18.8 million in 2021, then soared by 106.61% to $38.9 million in 2022, then surged by 107.65% to $80.7 million in 2023, then plummeted by 91.62% to $6.8 million in 2024, then surged by 64.24% to $11.1 million in 2025.
  • Its last three reported values are $11.1 million in Q3 2025, $7.6 million for Q2 2025, and $7.2 million during Q1 2025.